Definium Therapeutics, Inc. Common Shares (DFTX) Stock
Key stats
- Market cap
- $4.72B
- Price / Earnings ratio
- -14.1x
- EPS (TTM)
- -$3.02
- Volume
- Loading
- 52-week high
- $49.70
- 52-week low
- $10.46
Source: third-party data provider, as of November 13, 2026
Compare with DFTX
Recent news

Definium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics to Participate at Upcoming Investor Conferences
DFTX

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
DFTX

Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
DFTX

Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
DFTX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.92
- MACD 12/26/9
- -0.73
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.07
- SMA 50
- $36.31
- Price below SMA 50
- EMA 50
- $36.18
- Price below EMA 50
- SMA 200
- $30.27
- Price above SMA 200
- EMA 200
- $29.89
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Definium Therapeutics to Participate at Upcoming Investor Conferences
Definium Therapeutics to Participate at Upcoming Investor Conferences
DFTX

Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
DFTX

Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
DFTX

Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
DFTX

Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics Announces New Employee Inducement Grants
DFTX

Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
DFTX

Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
DFTX

Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run — Here Are The Stocks And Catalysts To Watch Next
DFTX

Definium Reports Second Phase III Success in Anxiety Disorder Program
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX

DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
DFTX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Definium Therapeutics, Inc. Common Shares
Definium Therapeutics’ mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by the belief that patients deserve more than incremental improvement, Definium is relentlessly advancing a new generation of therapeutics designed to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and help enable a healthier future. Headquartered in New York
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert Barrow | CEO & Director | 1989 |
| Ms. Brandi L. Roberts CPA, M.B.A. | Chief Financial Officer | 1974 |
| Dr. Daniel Rollings Karlin M.A., M.D. | Chief Medical Officer | 1980 |
| Dr. Scott M. Freeman M.D. | Co-Founder & Clinical Advisor | 1957 |
| Mr. Leonard Latchman | Co-Founder | — |
| Mr. Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | — |
| Ms. Gitanjali Jain Ogawa | VP & Head of Investor Relations | — |
| Mr. Mark R. Sullivan J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Ms. Beth Calitri | Vice President of Corporate Communications | — |
| Ms. Stephanie Fagan M.S. | Chief Corporate Affairs Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.92
- MACD 12/26/9
- -0.73
- EMA 9 of MACD
- -0.81
- MACD histogram
- 0.07
- SMA 50
- $36.31
- Price below SMA 50
- EMA 50
- $36.18
- Price below EMA 50
- SMA 200
- $30.27
- Price above SMA 200
- EMA 200
- $29.89
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $66.00
- Average
- $75.00
- High
- $90.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +9.8 | -4.3 | +10.0 | +6.2 | +11.5 | +95.5 | +0.3 | -5.0 | -1.1 | -3.4 | +6.2 |



